Abstract
Seizures have a variety of etiologies and manifestations. Descriptions of various epiletic seizures as well as electroencephalographic findings have led to a unifying international classification of epileptic seizures and epilepsy syndromes. The development of this classification system and the emergence of several new antiepiletic drugs have led to progress in the refractory pediatric patient particularly disorders which are traditionally difficult to treat such as infantile spasms and the Lennox-Gastaut Syndrome. However, there is limited data regarding optimal use in children. The childhood epilepsy syndromes are reviewed as well as the newer antiepileptic drug treatments felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, and zonisamide. Efficacy data and toxicity are discussed from both the adult, and when available, pediatric data.
Keywords: Childhood epilepsy, Epileptic syndromes, Seizures, Felbamate, Gabapentin, Lamotrigine, Levetiracetam, Oxcarbazepine, Tiagabine, Topiramate, Zonisamide, Electroencephalographic, Antiepilepsy drugs, Neonatal syndromes, Symptomatic, Cryptogenic, Adolescence, Lennox gastaut syndrome, Partial Seizures, Kojenikows syndrome, Rasmussens syndrome, Landau kleffner syndrome, Generalized tonic clonic seizures
Current Pharmaceutical Design
Title: Overview of Childhood Epilepsy and Epileptic Syndromes and Advances in Therapy
Volume: 6 Issue: 8
Author(s): L. D. Morton and J. M. Pellock
Affiliation:
Keywords: Childhood epilepsy, Epileptic syndromes, Seizures, Felbamate, Gabapentin, Lamotrigine, Levetiracetam, Oxcarbazepine, Tiagabine, Topiramate, Zonisamide, Electroencephalographic, Antiepilepsy drugs, Neonatal syndromes, Symptomatic, Cryptogenic, Adolescence, Lennox gastaut syndrome, Partial Seizures, Kojenikows syndrome, Rasmussens syndrome, Landau kleffner syndrome, Generalized tonic clonic seizures
Abstract: Seizures have a variety of etiologies and manifestations. Descriptions of various epiletic seizures as well as electroencephalographic findings have led to a unifying international classification of epileptic seizures and epilepsy syndromes. The development of this classification system and the emergence of several new antiepiletic drugs have led to progress in the refractory pediatric patient particularly disorders which are traditionally difficult to treat such as infantile spasms and the Lennox-Gastaut Syndrome. However, there is limited data regarding optimal use in children. The childhood epilepsy syndromes are reviewed as well as the newer antiepileptic drug treatments felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, and zonisamide. Efficacy data and toxicity are discussed from both the adult, and when available, pediatric data.
Export Options
About this article
Cite this article as:
Morton D. L. and Pellock M. J., Overview of Childhood Epilepsy and Epileptic Syndromes and Advances in Therapy, Current Pharmaceutical Design 2000; 6 (8) . https://dx.doi.org/10.2174/1381612003400281
DOI https://dx.doi.org/10.2174/1381612003400281 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Pharmacogenomics in Antiepileptic Drug Therapy: Current Status and Future Perspectives
Current Pharmaceutical Design SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology Magnolia officinalis Reduces Inflammation and Damage Induced by Recurrent Status Epilepticus in Immature Rats
Current Pharmaceutical Design Herbal Medicine in the Treatment of Epilepsy
Current Drug Targets Stem Cell Ageing and Apoptosis
Current Pharmaceutical Design Design, Synthesis, Anticonvulsant Activity, Preclinical Study and Pharmacokinetic Performance of N-{[3-(4-chlorophenyl)-4-oxo-3, 4-dihydroquinazolin- 2-yl] methyl}, 2-[(2-isopropyl-5-methyl) 1-cyclo Hexylidene] Hydrazinecarboxamide
Central Nervous System Agents in Medicinal Chemistry Prevention of Intracerebral Haemorrhage
Current Drug Targets In Silico Dynamic Molecular Interaction Networks for the Discovery of New Therapeutic Targets
Current Pharmaceutical Design Default Mode Network Connectivity and Related White Matter Disruption in Type 2 Diabetes Mellitus Patients Concurrent with Amnestic Mild Cognitive Impairment
Current Alzheimer Research Advanced Platelet-Rich Fibrin Extract Treatment Promotes the Proliferation and Differentiation of Human Adipose-Derived Mesenchymal Stem Cells through Activation of Tryptophan Metabolism
Current Stem Cell Research & Therapy Preparation of Tiagabine HCl/2-HPβCD Complex Pellets by Extrusion-Spheronization Using Glycerol Monostearate as Pellet-Aid
Letters in Drug Design & Discovery Meningitis Due to Cryptococcus neoformans: Treatment with Posaconazole
Current HIV Research Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design In Vitro Evaluation of Potential Hepatotoxicity Induced by Drugs
Current Pharmaceutical Design Voltage-Gated Sodium Channels and Pain
Current Drug Targets - CNS & Neurological Disorders Computational Methods Dedicated to Neurological Disorder Detection through Epistasis Analysis: A Review
Current Chinese Engineering Science The Medical Implications of Gastrointestinal Vagal Afferent Pathways in Nausea and Vomiting
Current Pharmaceutical Design Metabotropic Glutamate Receptors and Interacting Proteins in Epileptogenesis
Current Neuropharmacology Lamotrigine as an Effective Treatment for Behavioral Disorders
Letters in Drug Design & Discovery Imaging of Muscarinic Receptors in the Central Nervous System
Current Pharmaceutical Design